• www2.niddk.nih.gov/News/
  This webpage provides updates on current research from the NIDDK.

[Top]

• ClinicalTrials.gov
  ClinicalTrials.gov is a registry and results database of federally and privately supported clinical trials conducted in the United States and around the world. ClinicalTrials.gov gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details. This information should be used in conjunction with advice from health care professionals. ClinicalTrials.gov currently has 128,681 trials with locations in 180 countries.
• NIH Clinical Research Trials and You
  Learn more about clinical trials, why they matter, and how to participate by visiting this webpage. Clinical trials are research studies involving people. They form the basis of all medical advances. Clinical trials look at new ways to prevent, detect, or treat disease. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. To learn more about clinical trials, why they matter, and how to participate, visit the NIH Clinical Research Trials and You website at www.nih.gov/health/clinicaltrials.
• Studies at the NIH Clinical Center
  Patient studies under way at the NIH research hospital in Bethesda, Maryland.
• NIDDK Multi-Center Studies
  NIDDK-funded studies at locations across the United States.
  • Type 1 diabetes clinical studies are in particular need of volunteers.

[Top]

• Clinical Practice Guidelines
  The National Guideline Clearinghouse (NGC), a public resource for evidence-based clinical practice guidelines.

[Top]

• NIDDK Recent Advances and Emerging Opportunities
  The publication, NIDDK Recent Advances & Emerging Opportunities, is a document that the NIDDK has issued annually since 2001. It is a compendium that highlights examples of the many research advances published by NIDDK-funded scientists and their colleagues in the most recent fiscal year, along with the technologies that made these achievements possible. Thus, most of the research findings described in the February 2012 compendium were published in fiscal year 2011. In addition to research advances, the compendium includes:
  • “Stories of Discovery,” which trace research progress in specific areas over a much longer period of time;
  • “Scientific Presentations,” which have been made by eminent researchers during 2011; and
  • “Patient Profiles,” which recount the personal stories of several patients whose lives have been adversely affected by disease.
• NIDDK: 60 Years of Advancing Research to Improve Health
  This compendium celebrates the Institute’s accomplishments over the past 60 years in supporting and conducting research on some of the most common, chronic, and costly diseases affecting people in this country and around the world, as well as on diseases and disorders that are less widespread but nonetheless devastating in their impacts.

[Top]

• Collaborative Islet Transplant Registry (CITR)
  The mission of CITR is to expedite progress and promote safety in islet/beta cell transplantation through the collection, analysis, and communication of comprehensive and current data on all islet/beta cell transplants performed in North America and soon some transplants in Europe and Australia. An Annual Report is available on the public web site. This site serves as a repository for general information concerning protocols, clinical transplantation sites, publications, and other information of interest to the general community. More information is available from www.citregistry.org .
• Diabetes Control and Complications Trial (DCCT)
  A completed NIH study that showed how tight control of blood glucose can prevent complications in those with type 1 diabetes.
• Diabetes Prevention Trial—Type 1 (DPT-1)
  The Diabetes Prevention Trial—Type 1 (DPT-1) consisted of two clinical trials that sought to delay or prevent type 1 diabetes, also known as insulin-dependent diabetes. These efforts are being continued by the Type 1 Diabetes TrialNet consortium. More information about the DPT-1, funded under NIH clinical trial number NCT00004984, can be found at www.niddk.nih.gov/patient/dpt_1/dpt_1.htm.
• Immune Tolerance Network (ITN)
  The ITN is an international consortium of scientists and physicians dedicated to the clinical evaluation of novel tolerogenic approaches for the treatment of autoimmune diseases, asthma and allergic diseases, and the prevention of graft rejection. For more information, see www.immunetolerance.org or call 415–514–2530.
• The Environmental Determinants of Diabetes in the Young (TEDDY)
  This consortium is organizing international efforts to identify infectious agents, dietary factors, or other environmental factors that trigger type 1 diabetes in genetically susceptible people. More information about TEDDY, funded under NIH clinical trial number NCT00279318, can be found at http://teddy.epi.usf.edu .
• Trial to Reduce IDDM in the Genetically at Risk (TRIGR)
  The primary objective of this multi-center, international study is to determine whether weaning to a casein hydrolysate formula during the first 6-8 months of life in place of cow’s milk based formula reduces the incidence of autoimmunity and type 1 diabetes in genetically susceptible newborn infants. More information about the TRIGR study, funded under NIH clinical trial number NCT00179777, can be found at www.trigrnorthamerica.org/ or by calling 1–888–STOP–T1D (1–888–786–7813).
• Type 1 Diabetes Genetics Consortium (T1DGC)
  T1DGC was established with the primary goal of organizing international efforts to identify genes that determine an individual’s risk of type 1 diabetes. For more information, see www.t1dgc.org .
• Type 1 Diabetes TrialNet
  This clinical network seeks to prevent type 1 diabetes in high-risk people and to preserve insulin production in those newly diagnosed. More information about Type 1 Diabetes TrialNet, funded under NIH clinical trial number NCT00505206, can be found at www.DiabetesTrialNet.org or by calling 1–800–HALT–DM1 (1–800–425–8361).

[Top]

• Action for Health in Diabetes (Look AHEAD)
  This study is a 16-center, randomized clinical trial investigating the long-term health consequences of weight loss. The Look AHEAD cohort comprises approximately 5,000 overweight or obese participants with type 2 diabetes, aged 45-76. Participants were randomized to one of two interventions: an intensive lifestyle intervention designed to produce and sustain weight loss over the long term or a diabetes support and education arm. Participants will be followed for a total of 11 to 13.5 years from randomization. More information about the Look AHEAD study, funded under NIH clinical trial number NCT00017953, can be found at www.lookaheadstudy.org .
• Action to Control Cardiovascular Disease Risk in Diabetes (ACCORD)
  This NHLBI study is testing whether strict glucose control lowers the risk of heart disease and stroke in adults with type 2 diabetes. In addition the study is exploring two additional issues: 1) Whether in the context of good glycemic control the use of different lowering lipid drugs will further improve these outcomes and 2) If strict control of blood pressure will also have additional beneficial effects on reducing cardiovascular disease. More information about the ACCORD trial, funded under NIH clinical trial number NCT00000620, can be found at www.accordtrial.org/public/index.cfm .
• Bypass Angioplasty Revascularization Investigation (BARI) 2 Diabetes
  The NHLBI-led BARI 2D study aims to determine the best therapies for people with type 2 diabetes and moderately severe cardiovascular disease. More information about the BARI 2D trial, funded under NIH clinical trial number NCT00006305, can be found at www.Bari2D.org .
• Diabetes Prevention Program (DPP)
  The DPP showed that lifestyle change or metformin delay the development of type 2 diabetes. The DPPOS is a long-term follow-up study of the DPP participants.
  More information about the DPP, funded under NIH clinical trial number NCT00004992, is available at www.bsc.gwu.edu/dpp .
• Diabetes Prevention Program Outcomes Study (DPPOS)
  The Diabetes Prevention Program Outcomes Study is studying the long term effect of diet and exercise and the diabetes medication, metformin, on the delay of type 2 diabetes in participants of the Diabetes Prevention Program (DPP). More information about the DPPOS, funded under NIH clinical trial number NCT00038727, can be found at www.bsc.gwu.edu/dpp .
• HEALTHY
  The HEALTHY study, which seeks to prevent risk factors for type 2 diabetes in middle school children, began in September 2006. More information about the HEALTHY clinical trial, funded under NIH clinical trial number NCT00458029, can be found at www.healthystudy.org .
• TODAY Trial (Treatment Options for type 2 Diabetes in Adolescents and Youth)
  The TODAY study seeks to identify the best treatment of type 2 diabetes in children and teens. More information about the TODAY study, funded under NIH clinical trial number NCT00081328, can be found at www.todaystudy.org .

[Top]

• Conquering Diabetes: Highlights of Program Efforts, Research Advances and Opportunities-A Scientific Progress Report on the Diabetes Research Working Group's Strategic Plan
  A report that describes steps taken by the National Institutes of Health to implement the scientific recommendations made by the Diabetes Research Working Group, an independent, nongovernmental panel of experts.
• DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study
  Describes the results and implications of the DCCT, which was conducted by the NIDDK from 1983 to 1993 and showed that keeping blood glucose levels as close to normal as possible slows the onset and progression of the eye, kidney, and nerve damage caused by diabetes. Also describes the Epidemiology of Diabetes Interventions and Complications (EDIC) study, which is assessing the incidence and predictors of cardiovascular disease events and other diabetes complications by continuing to follow more than 90 percent of DCCT participants.
• Diabetes Prevention Program
  A completed NIH study that showed that people who follow a low-fat, low-calorie diet and who exercise 30 minutes a day, five times a week, have a far smaller risk of developing diabetes than these who don't.
• Diabetes, Type 1 (Yesterday, Today & Tomorrow: NIH Research Timelines) (from the National Institutes of Health)
• Diabetes, Type 2 (Yesterday, Today & Tomorrow: NIH Research Timelines) (from the National Institutes of Health)
• Special Statutory Funding Program for Type 1 Diabetes Research: Evaluation Report
  Summarizes the evaluation of the research programs supported by this special funding stream for research on type 1 diabetes and its complications. Describes the collaborative planning process guiding use of the funds, the research progress achieved to date, the expected future accomplishments of the programs, and emerging research opportunities.
• The Pima Indians: Pathfinders for Health
  A booklet that describes the role of the Pima Indians in helping to understand diabetes and details NIDDK's efforts to improve clinical care and self-management practices among this group.
• Type 1 Diabetes Research Funding and Clinical Trials
  The purpose of this website is to provide investigators with information on program funding opportunities; the research consortia and networks; and research resources that have been developed by the type 1 diabetes research consortia.

[Top]